The effect of 5-ASA and 4-ASA, drugs used for the treatment of inflammatory bowel disease, on modulation of experimental colitis and on colonic generation of interleukin-1 was evaluated. Three weeks of treatment with 5-ASA or 4-ASA (50 [igfkg) and one week of treatment with 5-ASA significantly decreased colonic interleukin-1 generation and the extent and severity of inflammation in a rat model of colitis induced by trinitrobenzene sulphonic acid. Colonic biopsies were obtained from patients with active ulcerative colitis and organ cultured 24 hours in the absence or presence of the following drugs: sulphasalazine, sulphapyridine, 5-ASA and 4-ASA (25-100 ,ug/ml). Interleukin-1 content in tissue cultured in the presence of 5-ASA (100 iglml) was two-thirds of its content in tissue cultured in drug free medium and its release into the medium was decreased by 50%. Sulphasalazine 50 ,tg/ml significantly decreased by 33% the tissue content but did not affect interleukin-1 release and a higher dose was not more effective. Sulphapyridine and 4-ASA in doses up to 100 [ig/ml did not affect either interleukin-1 colonic content or its release into the culture medium. We conclude that pharmacological suppression of colonic interleukin-1 generation may be one, although not the sole mechanism to explain the therapeutic efficacy of 5-ASA in the treatment of inflammatory bowel disease.
Recent studies have suggested a possible role of interleukin-1 in the pathogenesis of inflammatory bowel disease and experimental colitis. Peripheral blood mononuclear cells of Crohn's disease patients were shown to produce in vitro high quantities of interleukin-1 compared with normal control cells' and enhanced production of interleukin-1 beta was shown in colonic mononuclear cells ofpatients with inflammatory bowel disease.2 We have shown enhanced production of interleukin-1 by organ cultured colonic mucosa of patients with ulcerative colitis and Crohn's disease,3 most of which is derived from stimulated lamina propria mononuclear cells. 4 Enhanced generation of colonic interleukin-1 was shown also in three models of experimental colitis: in the chronic rat model of trinitrobenzene sulphonic acid induced colitis5; in the rabbit immune complex colitis6; and in a rabbit model of acute colitis induced by enteropathogenic E coli. 7 In view of the enhanced colonic generation of interleukin-l in models of experimental colitis and in patients with active inflammatory bowel disease and its possible contribution to the pathogenesis of the disease, it was logical to assume that drugs used in the treatment of inflammatory bowel disease may affect the generation of this cytokine. Corticosteroids which block interleukin-1 production by macrophages' were shown to inhibit its content as well as its release from the inflamed colonic mucosa of patients with ulcerative colitis.3 A dual cyclolipooxygenase inhibitor was shown to decrease colonic interleukin-1 synthesis in an experimental model of chronic colitis in rats. 5 The aim of the present study was to evaluate the possible modulation of experimental colitis by 5-ASA and 4-ASA and to determine the effect of sulphasalazine, its moieties, sulphapyridine and 5-ASA and 4-ASA on human colonic generation of interleukin-1 and, thus, to assess whether interference with its generation may be contributory to their therapeutic effects. The specimens were cultured (37°C, 5% C02, 95% air) for 24 hours, as described earlier.'`In brief, the tissue was placed on a metal grid over the central well of the culture dish (Falcon) containing the culture medium which consisted of0 7 ml RPMI 1640 (BioLab, Israel) containing penicillin (100 IU/ml) and streptomycin (100 ,tg/ml).
INTERLEUKIN-1 DETERMINATION
Cultured human colonic specimens, average weight 10 mg, or 50 mg ofthe rat colonic mucosal scrapings, were homogenised with a polytron homogeniser (Kinematic, Kriens-Lu, Switzerland) for 20 seconds at a speed grade of 6 in 0.5 ml 50 mM Tris HCl buffer, pH 7.4, containing 100 mM NaCI, 1 mM CaC12 and dextrose (1 mg/ 1 ml). These samples, as well as the samples of the cultured medium, were kept at -70°C until assayed for their interleukin-1 value.
Interleukin-1 activity was determined by its induction of interleukin-2 production by murine EL-4 cells as described previously." Briefly, 0.25 ml cultures of 2x 10 (5) EL-4 cells in a 96 well flat bottom plate are cocultured with the sample and 2x 10 (-7) M calcium ionophore A23187 for 24 hours. The culture fluids are then tested for interleukin-2 activity using the CTLL-20 interleukin-2 dependent cell line. The interleukin-2 activity is directly proportional to the input of interleukin-1. Units of interleukin-1 activity were calculated relative to a standard of pure recombinant human interleukin-1 beta prepared as described previously,'2 by a computer program described by Davis et al. '3 All tissue extracts were centrifuged at 10000 g for three minutes and filter sterilised before assay. STATISTICAL 
ANALYSIS
Statistical evaluation was performed according to the paired and unpaired Student's t test.
Results

EFFECT OF DRUGS ON EXPERIMENTAL COLITIS
The effect of treatment was evaluated using the macroscopic criteria of ulceration, stenosis, adhesions, and colonic impaction. Modulation of colonic damage was observed in nine of 11 rats treated with 5-ASA and in eight of eight rats treated with 4-ASA. The affected colonic segment was narrow but there were usually no ulcerations, faecal impaction or adhesions to adjacent organs. Treatment with 4-ASA also resulted in a significant (p<0 05) decrease in the wet weight of the affected segment -0-71 (0.06) g (mean (SEM)) as opposed to 1.2 (0-14) g in the control trinitrobenzene sulphonic acid/ethanol treated rats. In the 5-ASA treatment group, the wet weight was lower than in untreated rats but the difference did not reach statistical significance (Table I) (Tables I, II) . The generation of the eicosanoids TxB2 and LTB4 was also not affected after three weeks of treatment with 5-ASA or 4-ASA, or after one week of treatment with 5-ASA (Tables I, II) . On the other hand, after three weeks of therapy with 5-ASA and 4-ASA a significant decrease in mucosal interleukin-1 was observed when compared with trinitrobenzene sulphonic acid/ ethanol treated rats receiving no drugs (Table I) . One week of treatment with 5-ASA reduced mucosal interleukin-1 levels but not significantly (Table II) . EFFECT Interleukin-l (pJg)
4276 (1170) 2713 (1152) Colitis was induced by intracolonic administration of 0 25 ml 50% ethanol containing 30 mg trinitrobenzene sulphonic acid (TNB). Rats were treated daily with 5-ASA 50 mg/kg. Control rats were treated with vehicle only. After one week of treatment rats were killed, a 5 cm colonic segment proximal to the anus was isolated, weighed and the mucosa scraped for the determination of the inflammatory mediators, as described in Methods. Results are mean (SE). From each ulcerative colitis patient several mucosal specimens were obtained and cultured: one in the absence and one in each of the concentrations of sulphasalazine or 5-ASA (25-100 [Lg/ml).
Interleukin-1 content and release in cultures conducted without drugs was 51-0 (6.6) and 14-8 (2.4) (n=6) units/mg wet weight, respectively, and regarded as 100%. Results are mean (SE).
Significantly different from no drug. *p<0.01; tp<0 02 (t test for paired data).
in the cultured tissue specimens was 53.0 (6.3) pimg wet weight and its accumulation in the cultured medium was 12.4 (1.7) units/mg wet weightx(SE) (n=12). The effect of the drugs (100 .tg/ml) on mucosal interleukin-1 content and on its release to the medium is presented in the Figure. Mucosal interleukin-1 content and its release in cultures conducted in drug free medium was regarded as 100%. Only 5-ASA significantly decreased interleukin-1 colonic content and its release during 24 hours of culture. Interleukin-1 content in colonic mucosa cultured in the presence of 5-ASA was two-thirds of its content in tissue cultured in drug free medium. Interleukin-1 release into the medium containing 5-ASA was 50% of its release when cultured in drug free medium. 5-ASA concentrations lower than 100 [ig/ml had no effect (Table   III) . Sulphasalazine (50 ,ug/ml) significantly decreased interleukin-1 content but did not significantly affect its release into the medium. A higher concentration of 100 [ig/ml did not further decrease the tissue content and also did not affect its release into the medium (Table III) . Sulphapyridine and 4-ASA did not significantly affect either interleukin-1 content in the mucosa or its release into the culture medium.
Discussion
We have previously shown that the interleukin-1 bioassay used in the present study is in good colitis'6 and in the maintenance of the disease in remission.'7 5-ASA was previously shown to also inhibit the generation of human colonic prostanoids,'0 leukotrienes,'8 and the platelet activating factor -potential mechanisms to explain its therapeutic effects.
The injury induced by trinitrobenzene sulphonic acid/ethanol is definitely extensive. It is difficult to anticipate that any drug would be able to prevent the development of the inflammatory response to this severe insult, to modify its propagation or the generation of the inflammatory mediators. Yet, in the present study, 5-ASA was found to significantly affect interleukin-1 generation, although none ofthe other mediators determined -TxB2 and LTB4. In addition, the majority of rats treated with 5-ASA could be blindly identified, both macroscopically and histologically, indicating its therapeutic effect. It, therefore, seems that 5-ASA is a potent inhibitor of interleukin-1 generation, which may definitely contribute towards its antiinflammatory properties.
Sulphapyridine had no effect on human colonic interleukin-1 generation whereas sulphasalazine significantly decreased only its tissue content but did not affect its release. Sulphapyridine does not affect the generation of any of the other inflammatory mediators'" '9 and is not considered effective in the treatment of inflammatory bowel disease.'5 Sulphasalazine, on the other hand, inhibits, although to a lesser extent than 5-ASA, the generation of colonic eicosanoids,"' and the platelet aggregation factor. '9 As the therapeutic efficacy of sulphasalazine and 5-ASA is similar,'67 it would appear that this efficacy cannot only be ascribed to their effects on one or all of the inflammatory mediators. Yet, if inhibition of the generation of inflammatory mediators is of importance only, 5-ASA share with corticosteroids2" significant inhibition of the colonic generation of prostanoids,"'°leuko-trienes,"' the platelet aggregation factor'9 and, as herewith shown, also of interleukin-l1. 4 -ASA is also claimed to be of benefit in the treatment of ulcerative colitis.2' The mechanism responsible for its therapeutic efficacy is not well defined. In the present study it was found to modulate an experimental model of chronic colitis in which it significantly decreased colonic interleukin-1 generation but had no effect on human colonic interleukin-1 generation. The discrepancy between the effect of 4-ASA on human and rat colonic interleukin-1 generation casts doubts on the importance of blocking the generation of colonic interleukin-1 as the sole, important mechanism to explain the therapeutic effects of 4-ASA as well as the other drugs currently used for the treatment of inflammatory bowel disease.
